{
    "info": {
        "nct_id": "NCT01980472",
        "official_title": "Phase II Trial of Geriatric Evaluation as Selection Criteria and Predictive Factor of Safety in Elderly Patients (≥ 70 Years) With Non-small Cell Lung Cancer (NSCLC)That Can be Treated With Bevacizumab, Carboplatin and Paclitaxel",
        "inclusion_criteria": "* Written informed consent confirming that the patient understands the study objective and the procedures required.\n* Patients must be able to accomplish with the study protocol.\n* Men and women ≥70 years old.\n* Histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer (NSCLC) with EGFR gen mutational status negative or non-determinable.\n* Patients with stage IV disease.\n* Patients who have not received first-line treatment\n* Patients with ECOG performance status 0 or 1.\n* Adequate bone marrow function, defined as:\n\nAbsolute neutrophil count (ANC) ≥1.500/mm3 or ≥1.5x109/L; Hemoglobin ≥ 9 g/dL. Platelet count ≥ 100.000/mm3. • Adequate renal function, defined as: Creatinine clearance ≥ 40 ml/min, according to MDRD formula. Urine dipstick proteinuria <2+. If urine dipstick for proteinuria ≥2+ 24 hours urine must be collected within 24 hours, and proteins must be less than 1 g.\n\n• Fertile males must use an effective contraceptive method (error rate per year <1%) during the trial and until 6 months after the last study treatment dose, such as sexual abstinence, previous vasectomy and/or having a partner using any of following methods: implantables, injections, combined oral contraceptives and/or intrauterine device (hormonal only).\nHealthy volunteers allowed\nMust have minimum age of 70 Years\nMust have maximum age of 85 Years",
        "exclusion_criteria": "* Previous chemotherapy for advanced NSCLC.\n* History of haemoptysis grade ≥ 2 (defined as at least 2.5 mL of bright red blood) in the 3 months before inclusion.\n* Major surgery (including open biopsy), significant traumatic injuries in the 28 days before inclusion or anticipation of the need of major surgical procedure during the treatment period\n* Minor surgery, including permanent catheter insertion, in the 24 hours before bevacizumab infusion.\n* Untreated brain metastases. Patients with CNS metastases treated with radiotherapy or surgery may be included if there is no evidence of progression after treatment\n* Radiological evidence of a tumor that invades or is adjacent to a main blood vessel (e.g. lung artery or superior cava venous).\n* Radiotherapy, in any lesion and for any reason, within 28 days before inclusion. Palliative radiotherapy for bone lesions within 14 days before inclusion is allowed.\n* Treatment with aspirin (>325 mg/day) or clopidogrel (>75 mg/day) within 10 days prior to bevacizumab first dose. Use of full dose of oral or parenteral anticoagulants or thrombolytic agents in therapeutic doses. Prophylactic use of anticoagulant therapy is allowed.\n* Uncontrolled hypertension (systolic BP >140 mmHg, diastolic BP >90mmHg) in the 28 days previous to inclusion or history of hypertensive crisis , or hypertensive encephalopathy.\n* Clinically significant cardiovascular disease (i.e. cerebrovascular accident (CVA), myocardial infarction within 6 months prior to inclusion, unstable angina, congestive cardiac insufficiency NYHA ≥ II, left ventricular ejection fraction (LVEF) <50% or serious cardiac arrhythmia), not responding to treatment or that can interfere with trial treatment administration.\n* Not healed wounds, active peptic ulcer or untreated bone fracture.\n* Hypersensibility to any of the active ingredients of the study treatment (bevacizumab, carboplatine and paclitaxel) or any of its excipients.\n* Serious cognitive impairment that limits the patient to understand and answer the study questionnaires.\n* Inability to comply with the study protocol and/or follow-up procedures due to psychological, familiar, social or geographical problems\n* Patients with an ADL score <5 at the screening.\n* Patients with dementia: 9-12 points in the Folstein MMS at the screening.\n* Patients accomplishing fragility Balducci criteria at the screening:\n\nAge ≥ 85 years old Dependence in 1 or more ADL >3 comorbidities >1 geriatric syndrome",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Written informed consent confirming that the patient understands the study objective and the procedures required.",
            "criterions": [
                {
                    "exact_snippets": "Written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "confirming that the patient understands the study objective and the procedures required",
                    "criterion": "understanding of study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be able to accomplish with the study protocol.",
            "criterions": [
                {
                    "exact_snippets": "Patients must be able to accomplish with the study protocol.",
                    "criterion": "ability to comply with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men and women ≥70 years old.",
            "criterions": [
                {
                    "exact_snippets": "Men and women",
                    "criterion": "gender",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "≥70 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer (NSCLC) with EGFR gen mutational status negative or non-determinable.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer (NSCLC)",
                    "criterion": "non-squamous non-small cell lung cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "EGFR gen mutational status negative or non-determinable",
                    "criterion": "EGFR gen mutational status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "negative",
                                "non-determinable"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with stage IV disease.",
            "criterions": [
                {
                    "exact_snippets": "stage IV disease",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have not received first-line treatment",
            "criterions": [
                {
                    "exact_snippets": "Patients who have not received first-line treatment",
                    "criterion": "first-line treatment",
                    "requirements": [
                        {
                            "requirement_type": "receipt",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with ECOG performance status 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate bone marrow function, defined as:",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone marrow function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Absolute neutrophil count (ANC) ≥1.500/mm3 or ≥1.5x109/L; Hemoglobin ≥ 9 g/dL. Platelet count ≥ 100.000/mm3. • Adequate renal function, defined as: Creatinine clearance ≥ 40 ml/min, according to MDRD formula. Urine dipstick proteinuria <2+. If urine dipstick for proteinuria ≥2+ 24 hours urine must be collected within 24 hours, and proteins must be less than 1 g.",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥1.500/mm3 or ≥1.5x109/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1.5,
                                        "unit": "x10^9/L"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Hemoglobin ≥ 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 9,
                                        "unit": "g/dL"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Platelet count ≥ 100.000/mm3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 100000,
                                        "unit": "mm3"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate renal function, defined as: Creatinine clearance ≥ 40 ml/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 40,
                                        "unit": "ml/min"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Urine dipstick proteinuria <2+",
                    "criterion": "urine dipstick proteinuria",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 2,
                                        "unit": "+"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If urine dipstick for proteinuria ≥2+ 24 hours urine must be collected within 24 hours, and proteins must be less than 1 g",
                    "criterion": "24-hour urine protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 1,
                                        "unit": "g"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "• Fertile males must use an effective contraceptive method (error rate per year <1%) during the trial and until 6 months after the last study treatment dose, such as sexual abstinence, previous vasectomy and/or having a partner using any of following methods: implantables, injections, combined oral contraceptives and/or intrauterine device (hormonal only).",
            "criterions": [
                {
                    "exact_snippets": "Fertile males must use an effective contraceptive method",
                    "criterion": "fertility",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "effective contraceptive method (error rate per year <1%)",
                    "criterion": "contraceptive method effectiveness",
                    "requirements": [
                        {
                            "requirement_type": "error rate per year",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "during the trial and until 6 months after the last study treatment dose",
                    "criterion": "contraceptive method duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the trial and until 6 months after the last study treatment dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "such as sexual abstinence, previous vasectomy and/or having a partner using any of following methods: implantables, injections, combined oral contraceptives and/or intrauterine device (hormonal only)",
                    "criterion": "contraceptive method type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "sexual abstinence",
                                "previous vasectomy",
                                "partner using implantables",
                                "partner using injections",
                                "partner using combined oral contraceptives",
                                "partner using intrauterine device (hormonal only)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 70 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 70 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 85 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 85 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 85,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Previous chemotherapy for advanced NSCLC.",
            "criterions": [
                {
                    "exact_snippets": "Previous chemotherapy for advanced NSCLC",
                    "criterion": "chemotherapy for advanced NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of haemoptysis grade ≥ 2 (defined as at least 2.5 mL of bright red blood) in the 3 months before inclusion.",
            "criterions": [
                {
                    "exact_snippets": "History of haemoptysis grade ≥ 2",
                    "criterion": "haemoptysis grade",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 2.5 mL of bright red blood",
                    "criterion": "haemoptysis volume",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the 3 months before inclusion",
                    "criterion": "time since last haemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery (including open biopsy), significant traumatic injuries in the 28 days before inclusion or anticipation of the need of major surgical procedure during the treatment period",
            "criterions": [
                {
                    "exact_snippets": "Major surgery (including open biopsy) ... in the 28 days before inclusion",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since occurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "significant traumatic injuries in the 28 days before inclusion",
                    "criterion": "significant traumatic injuries",
                    "requirements": [
                        {
                            "requirement_type": "time since occurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of the need of major surgical procedure during the treatment period",
                    "criterion": "need of major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "anticipated during treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Minor surgery, including permanent catheter insertion, in the 24 hours before bevacizumab infusion.",
            "criterions": [
                {
                    "exact_snippets": "Minor surgery, including permanent catheter insertion, in the 24 hours before bevacizumab infusion.",
                    "criterion": "minor surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "hours before bevacizumab infusion"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "permanent catheter insertion, in the 24 hours before bevacizumab infusion.",
                    "criterion": "permanent catheter insertion",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "hours before bevacizumab infusion"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Untreated brain metastases. Patients with CNS metastases treated with radiotherapy or surgery may be included if there is no evidence of progression after treatment",
            "criterions": [
                {
                    "exact_snippets": "Untreated brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "CNS metastases treated with radiotherapy or surgery ... no evidence of progression after treatment",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "radiotherapy",
                                "surgery"
                            ]
                        },
                        {
                            "requirement_type": "progression",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiological evidence of a tumor that invades or is adjacent to a main blood vessel (e.g. lung artery or superior cava venous).",
            "criterions": [
                {
                    "exact_snippets": "Radiological evidence of a tumor",
                    "criterion": "tumor",
                    "requirements": [
                        {
                            "requirement_type": "detection method",
                            "expected_value": "radiological evidence"
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor that invades or is adjacent to a main blood vessel",
                    "criterion": "tumor location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "invades or is adjacent to a main blood vessel"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiotherapy, in any lesion and for any reason, within 28 days before inclusion. Palliative radiotherapy for bone lesions within 14 days before inclusion is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Radiotherapy, in any lesion and for any reason, within 28 days before inclusion.",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Palliative radiotherapy for bone lesions within 14 days before inclusion is allowed.",
                    "criterion": "palliative radiotherapy for bone lesions",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with aspirin (>325 mg/day) or clopidogrel (>75 mg/day) within 10 days prior to bevacizumab first dose. Use of full dose of oral or parenteral anticoagulants or thrombolytic agents in therapeutic doses. Prophylactic use of anticoagulant therapy is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with aspirin (>325 mg/day)",
                    "criterion": "aspirin treatment",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 325,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 10 days prior to bevacizumab first dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... clopidogrel (>75 mg/day)",
                    "criterion": "clopidogrel treatment",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 75,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 10 days prior to bevacizumab first dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of full dose of oral or parenteral anticoagulants or thrombolytic agents in therapeutic doses",
                    "criterion": "anticoagulant or thrombolytic agent use",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": "therapeutic doses"
                        }
                    ]
                },
                {
                    "exact_snippets": "Prophylactic use of anticoagulant therapy is allowed",
                    "criterion": "prophylactic anticoagulant therapy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension (systolic BP >140 mmHg, diastolic BP >90mmHg) in the 28 days previous to inclusion or history of hypertensive crisis , or hypertensive encephalopathy.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "systolic BP >140 mmHg",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 140,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic BP >90mmHg",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of hypertensive crisis",
                    "criterion": "hypertensive crisis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypertensive encephalopathy",
                    "criterion": "hypertensive encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant cardiovascular disease (i.e. cerebrovascular accident (CVA), myocardial infarction within 6 months prior to inclusion, unstable angina, congestive cardiac insufficiency NYHA ≥ II, left ventricular ejection fraction (LVEF) <50% or serious cardiac arrhythmia), not responding to treatment or that can interfere with trial treatment administration.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular disease (i.e. cerebrovascular accident (CVA)",
                    "criterion": "cerebrovascular accident (CVA)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant cardiovascular disease ... myocardial infarction within 6 months prior to inclusion",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant cardiovascular disease ... unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant cardiovascular disease ... congestive cardiac insufficiency NYHA ≥ II",
                    "criterion": "congestive cardiac insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant cardiovascular disease ... left ventricular ejection fraction (LVEF) <50%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant cardiovascular disease ... serious cardiac arrhythmia",
                    "criterion": "serious cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not responding to treatment",
                    "criterion": "response to treatment",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "can interfere with trial treatment administration",
                    "criterion": "interference with trial treatment administration",
                    "requirements": [
                        {
                            "requirement_type": "potential",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Not healed wounds, active peptic ulcer or untreated bone fracture.",
            "criterions": [
                {
                    "exact_snippets": "Not healed wounds",
                    "criterion": "wounds",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "not healed"
                        }
                    ]
                },
                {
                    "exact_snippets": "active peptic ulcer",
                    "criterion": "peptic ulcer",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated bone fracture",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hypersensibility to any of the active ingredients of the study treatment (bevacizumab, carboplatine and paclitaxel) or any of its excipients.",
            "criterions": [
                {
                    "exact_snippets": "Hypersensibility to any of the active ingredients of the study treatment (bevacizumab, carboplatine and paclitaxel)",
                    "criterion": "hypersensitivity to active ingredients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Hypersensibility to ... any of its excipients",
                    "criterion": "hypersensitivity to excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serious cognitive impairment that limits the patient to understand and answer the study questionnaires.",
            "criterions": [
                {
                    "exact_snippets": "Serious cognitive impairment",
                    "criterion": "cognitive impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                },
                {
                    "exact_snippets": "limits the patient to understand and answer the study questionnaires",
                    "criterion": "ability to understand and answer study questionnaires",
                    "requirements": [
                        {
                            "requirement_type": "limitation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to comply with the study protocol and/or follow-up procedures due to psychological, familiar, social or geographical problems",
            "criterions": [
                {
                    "exact_snippets": "Inability to comply with the study protocol and/or follow-up procedures due to psychological ... problems",
                    "criterion": "psychological problems",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Inability to comply with the study protocol and/or follow-up procedures due to ... familiar ... problems",
                    "criterion": "familiar problems",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Inability to comply with the study protocol and/or follow-up procedures due to ... social ... problems",
                    "criterion": "social problems",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Inability to comply with the study protocol and/or follow-up procedures due to ... geographical problems",
                    "criterion": "geographical problems",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with an ADL score <5 at the screening.",
            "criterions": [
                {
                    "exact_snippets": "ADL score <5",
                    "criterion": "ADL score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with dementia: 9-12 points in the Folstein MMS at the screening.",
            "criterions": [
                {
                    "exact_snippets": "dementia",
                    "criterion": "dementia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "9-12 points in the Folstein MMS",
                    "criterion": "Folstein MMS score",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 9,
                                        "unit": "points"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "points"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients accomplishing fragility Balducci criteria at the screening:",
            "criterions": [
                {
                    "exact_snippets": "fragility Balducci criteria",
                    "criterion": "fragility Balducci criteria",
                    "requirements": [
                        {
                            "requirement_type": "accomplishment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Age ≥ 85 years old Dependence in 1 or more ADL >3 comorbidities >1 geriatric syndrome",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 85 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 85,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Dependence in 1 or more ADL",
                    "criterion": "ADL dependence",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "ADL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": ">3 comorbidities",
                    "criterion": "comorbidities",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "comorbidities"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": ">1 geriatric syndrome",
                    "criterion": "geriatric syndromes",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "geriatric syndromes"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}